ISSUER NEWS - JAKARTA. Hospital issuer, PT Sejahteraraya Anugrahjaya Tbk (SRAJ), or Mayapada Healthcare Group is targeting a positive business increase in 2024.
Mayapada Healthcare Group's Corporate Secretary Arie Farisandi stated that SRAJ estimates revenue growth in 2024 will reach 30% compared to last year. This optimism takes into account the potential of the health market in Indonesia which continues to grow.
In addition, SRAJ management also takes various initiatives to develop its business, such as hospital unit renovations, and health service expansions.
"And collaboration with renowned hospital networks in the world," revealed Arie, to Kontan.co.id, Wednesday (24/1).
For example, SRAJ has renovated Mayapada Hospital Tangerang and Mayapada Hospital Bogor, most of which were completed in 2023 and can be fully operational in 2024.
Not stopping there, SRAJ also improves the performance of new hospitals, such as Mayapada Hospital Surabaya and Bandung.
Read Also: President Jokowi Continues to Groundbreaking the IKN Project
Then, SRAJ also expand services such as the procurement of Smart Fertility Clinic services at Mayapada Hospital Bogor and In-vitro Fertilization (IVF) at Mayapada Hospital South Jakarta which will support the growth of the Pediatric Center of Excellence (CoE) service center.
"The company also collaborates with the National University Hospital (NUH) Singapore and Apollo Hospital India - one of the largest health networks in the world - to continuously improve the performance of medical personnel in the Mayapada Hospital network so that they can provide the best service and perform more advanced medical actions," explained Arie.
By the end of 2023, there are already six Mayapada Hospitals in operation, namely Mayapada Hospital Tangerang, Mayapada Hospital South Jakarta, Mayapada Hospital Bogor, Mayapada Hospital Kuningan, Mayapada Hospital Surabaya and Mayapada Hospital Bandung.
Regarding financial performance, SRAJ is currently conducting a financial audit for the 2023 fiscal year, but it is estimated that revenue in 2023 will be in the range of IDR 2.5 trillion or up 29% year on year (YoY) compared to 2022 and EBITDA grew 53% compared to 2022.